GlaxoSmithKline (GSK) has agreed to sell the majority of its portfolio of non-promoted, genericised drugs in Australia to South Africa's Aspen Pharmacare for approximately £172 M (US$270 M) in cash. These 25 ‘classic brands’ include Valtrex® (valaciclovir), Lamictal® (lamotrigine) and Amoxil® (amoxicillin) and together recorded sales of approximately £83 M (US$133 M) in 2011. The deal is the latest example of GSK’s strategy of divesting low-growth or non-core businesses in order to focus on priority brands and enhance shareholder returns.